DermTech, Inc. (DMTK) News
Filter DMTK News Items
DMTK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DMTK News Highlights
- DMTK's 30 day story count now stands at 5.
- Over the past 21 days, the trend for DMTK's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about DMTK are SKIN, DMAC and SUN.
Latest DMTK News From Around the Web
Below are the latest news stories about DERMTECH INC that investors may wish to consider to help them evaluate DMTK as an investment opportunity.
DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4)SAN DIEGO, September 21, 2023--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that DermTech’s Compensation Committee has granted an equity award to its new chief commercial officer, Mark Aguillard. The award was granted pursuant to the terms of Mr. Aguillard’s employment letter and as a material inducement to his joining the Company as chief commercial officer. |
DermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT)SAN DIEGO, September 19, 2023--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced agreements with Highmark Inc. (Highmark). The contracts, which are in addition to a favorable coverage policy, enhance access to the foundational assay of the DermTech Melanoma Test (DMT). Highmark and its Blue-branded affiliates provide health insurance to approximately 7 million members in Pennsylvania, Wes |
Insider Sell: DermTech Inc CFO Kevin Sun Sells 9,616 SharesOn September 11, 2023, Kevin Sun, the Chief Financial Officer (CFO) of DermTech Inc (NASDAQ:DMTK), sold 9,616 shares of the company. |
DermTech Appoints Mark Aguillard as Chief Commercial OfficerSAN DIEGO, September 11, 2023--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the appointment of Mark Aguillard as chief commercial officer effective September 19, 2023. Mr. Aguillard will lead DermTech’s overall commercial strategy and execution. |
Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?Here is how DiaMedica Therapeutics, Inc. (DMAC) and DermTech, Inc. (DMTK) have performed compared to their sector so far this year. |
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, August 25, 2023--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the grant to six new employees of restricted stock units representing the contingent right to receive up to an aggregate of 24,720 shares of the Company’s common stock under its 2022 Inducement Equity Incentive Plan, as amended, or the 2022 Inducement Plan. The restricted stock units were approved by DermTec |
DermTech (NASDAQ:DMTK) Will Have To Spend Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
DermTech, Inc. (DMTK) Reports Q2 Loss, Tops Revenue EstimatesDermTech, Inc. (DMTK) delivered earnings and revenue surprises of -4.21% and 12.11%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
DermTech Reports Second-Quarter 2023 Financial ResultsSAN DIEGO, August 03, 2023--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its second-quarter 2023 financial results. |
DermTech Announces Favorable Coverage Policy With Blues Plan in Michigan for the Foundational Assay of Its DermTech Melanoma Test (DMT)SAN DIEGO, July 19, 2023--DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced a favorable coverage policy with a Blues plan in Michigan. The favorable coverage policy, which is in addition to a contract that became effective in August 2022, enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the approximately 4.5 million members of this plan. The Pigmented Lesi |